niclosamide has been researched along with Diabetes Mellitus, Type 2 in 8 studies
Niclosamide: An antihelmintic that is active against most tapeworms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p48)
niclosamide : A secondary carboxamide resulting from the formal condensation of the carboxy group of 5-chlorosalicylic acid with the amino group of 2-chloro-4-nitroaniline. It is an oral anthelmintic drug approved for use against tapeworm infections.
Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
Excerpt | Relevance | Reference |
---|---|---|
"Niclosamide piperazine salt may hold the promise to become an alternative to NEN as a drug lead for the treatment of obesity and T2D." | 7.91 | Niclosamide piperazine prevents high-fat diet-induced obesity and diabetic symptoms in mice. ( Alasadi, A; Guo, J; Huang, Q; Jin, S; Tao, H, 2019) |
"Niclosamide is an oral antihelminthic drug used to treat parasitic infections in millions of people worldwide." | 4.98 | Niclosamide: Beyond an antihelminthic drug. ( Chen, W; Mook, RA; Premont, RT; Wang, J, 2018) |
"Niclosamide piperazine salt may hold the promise to become an alternative to NEN as a drug lead for the treatment of obesity and T2D." | 3.91 | Niclosamide piperazine prevents high-fat diet-induced obesity and diabetic symptoms in mice. ( Alasadi, A; Guo, J; Huang, Q; Jin, S; Tao, H, 2019) |
"Metabolic disorders such as type 2 diabetes, fatty liver disease, hyperlipidemia, and obesity commonly co-occur but clinical treatment options do not effectively target all disorders." | 2.44 | Head-to-head comparison of BAM15, semaglutide, rosiglitazone, NEN, and calorie restriction on metabolic physiology in female db/db mice. ( Alexopoulos, SJ; Beretta, M; Byrne, FL; Cantley, J; Chen, SY; Garcia, CJ; Hoehn, KL; Larance, M; Olzomer, EM; Philp, A; Salamoun, JM; Santos, WL; Shah, DP; Smith, GC; Turner, N, 2024) |
"Diabetic peripheral neuropathy (DPN), diabetic kidney disease (DKD), and diabetic retinopathy (DR) contribute to significant morbidity and mortality in diabetes patients." | 1.51 | Mitochondrial uncoupling has no effect on microvascular complications in type 2 diabetes. ( Abcouwer, SF; Backus, C; Brosius, FC; Feldman, EL; Hayes, JM; Hinder, LM; Kayampilly, P; Lin, CM; O'Brien, PD; Pennathur, S; Rumora, AE; Sas, KM; Shanmugam, S; Zhang, H, 2019) |
"Early diabetic kidney disease (DKD) is characterized by renal hypertrophy and albuminuria." | 1.48 | Niclosamide ethanolamine improves kidney injury in db/db mice. ( Ge, N; Han, P; Li, S; Shao, M; Song, G; Sun, H; Wang, W; Yi, T; Yu, X; Zhan, H; Zhang, C, 2018) |
" Although the pharmacokinetic properties of NIC are appropriate for use as an anthelmintic agent, its low solubility, low bioavailability and low systemic exposure limit its usefulness in treating systemic diseases." | 1.46 | Niclosamide-conjugated polypeptide nanoparticles inhibit Wnt signaling and colon cancer growth. ( Bhattacharyya, J; Chen, W; Chilkoti, A; Li, X; Mook, RA; Premont, RT; Ren, XR; Spasojevic, I; Wang, J, 2017) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 7 (87.50) | 24.3611 |
2020's | 1 (12.50) | 2.80 |
Authors | Studies |
---|---|
Chen, SY | 1 |
Beretta, M | 1 |
Olzomer, EM | 1 |
Alexopoulos, SJ | 1 |
Shah, DP | 1 |
Byrne, FL | 1 |
Salamoun, JM | 1 |
Garcia, CJ | 1 |
Smith, GC | 3 |
Larance, M | 1 |
Philp, A | 1 |
Turner, N | 2 |
Santos, WL | 1 |
Cantley, J | 1 |
Hoehn, KL | 1 |
Chen, W | 2 |
Mook, RA | 2 |
Premont, RT | 2 |
Wang, J | 2 |
Guo, J | 1 |
Tao, H | 1 |
Alasadi, A | 1 |
Huang, Q | 1 |
Jin, S | 1 |
Bhattacharyya, J | 1 |
Ren, XR | 1 |
Spasojevic, I | 1 |
Li, X | 1 |
Chilkoti, A | 1 |
Han, P | 1 |
Zhan, H | 1 |
Shao, M | 1 |
Wang, W | 1 |
Song, G | 1 |
Yu, X | 1 |
Zhang, C | 1 |
Ge, N | 1 |
Yi, T | 1 |
Li, S | 1 |
Sun, H | 1 |
Hinder, LM | 1 |
Sas, KM | 1 |
O'Brien, PD | 1 |
Backus, C | 1 |
Kayampilly, P | 1 |
Hayes, JM | 1 |
Lin, CM | 1 |
Zhang, H | 1 |
Shanmugam, S | 1 |
Rumora, AE | 1 |
Abcouwer, SF | 1 |
Brosius, FC | 1 |
Pennathur, S | 1 |
Feldman, EL | 1 |
Chowdhury, MK | 2 |
Wu, LE | 2 |
Coleman, JL | 1 |
Smith, NJ | 1 |
Morris, MJ | 2 |
Shepherd, PR | 2 |
Bentley, NL | 1 |
Das, A | 1 |
Richani, D | 1 |
Bustamante, S | 1 |
Gilchrist, RB | 1 |
1 review available for niclosamide and Diabetes Mellitus, Type 2
Article | Year |
---|---|
Niclosamide: Beyond an antihelminthic drug.
Topics: Animals; Anthelmintics; Arthritis, Rheumatoid; Diabetes Mellitus, Type 2; Disease Models, Animal; En | 2018 |
7 other studies available for niclosamide and Diabetes Mellitus, Type 2
Article | Year |
---|---|
Head-to-head comparison of BAM15, semaglutide, rosiglitazone, NEN, and calorie restriction on metabolic physiology in female db/db mice.
Topics: Animals; Caloric Restriction; Diabetes Mellitus, Type 2; Ethanolamine; Ethanolamines; Female; Mice; | 2024 |
Niclosamide piperazine prevents high-fat diet-induced obesity and diabetic symptoms in mice.
Topics: Animals; Diabetes Mellitus, Type 2; Diet, High-Fat; Disease Models, Animal; Insulin Resistance; Mice | 2019 |
Niclosamide-conjugated polypeptide nanoparticles inhibit Wnt signaling and colon cancer growth.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Diabetes Mellitus, Type 2; Humans; | 2017 |
Niclosamide ethanolamine improves kidney injury in db/db mice.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Ethanol | 2018 |
Mitochondrial uncoupling has no effect on microvascular complications in type 2 diabetes.
Topics: Animals; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diabetic Neuropathies; Diabetic Retinopa | 2019 |
Niclosamide blocks glucagon phosphorylation of Ser552 on β-catenin in primary rat hepatocytes via PKA signalling.
Topics: Animals; beta Catenin; Bucladesine; Cyclic AMP-Dependent Protein Kinases; Diabetes Mellitus, Type 2; | 2016 |
Niclosamide reduces glucagon sensitivity via hepatic PKA inhibition in obese mice: Implications for glucose metabolism improvements in type 2 diabetes.
Topics: Animals; Body Composition; Body Weight; Cyclic AMP-Dependent Protein Kinases; Diabetes Mellitus, Typ | 2017 |